Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Investors follow market indices to gauge performance, set expectations, and benchmark risk. Indices provide a common frame for evaluating results.
28,426 articlesA cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Tech giants push AI-led gains as the Nasdaq plays catch-up, with policy updates and earnings previews guiding a cauti...
Rivian shares jumped about 8% amid a crucial R2 production debut and rising software revenue, even as peers Tesla and...
ACV Auctions delivered strong fourth-quarter numbers and a hopeful 2026 outlook, but shares plunged as investors weig...
Global demand for AI-enabled services meets market volatility. This guide breaks down Globant's strategy, risks, and ...
A little-known rival to SCHD has delivered competitive long-run gains and steady monthly income, thanks to a mid-cap ...
A lightweight but powerful AI platform is emerging as the newest winner cheaper than Anthropic, with early profitabil...
Chevron announces a quarterly dividend of $1.78 per share, marking 39 years of uninterrupted growth. Q4 results show ...
Markets sprinted to a milestone in the first week under a Warsh-led policy stance. The S&P 500 posted seven straight ...
Geopolitical tensions tend to spark short-term volatility, but long-term market outcomes hinge on fundamentals. This ...
As coastal rents climb, a growing number of investors are testing a bold concept: a $310,000 portfolio that pays enou...
Ulta Beauty shares have tumbled in the wake of earnings, but analysts see a potential entry point. The ulta beauty pr...